← Search & browse all drugs
VARIOUS › DIAGNOSTIC RADIOPHARMACEUTICALS › INFLAMMATION AND INFECTION DETECTION › Technetium (99mTc) compounds
technetium (99mTc) antigranulocyte antibody
V09HA03
Forms & Strengths
- Sterile lyophilized kit containing 10‑30 mg murine anti‑granulocyte antibody (fragment) per vial
- Reconstituted with 99mTc pertechnetate to yield 10‑30 mCi (370‑1110 MBq) radiolabel per dose
- Single‑use vial for intravenous injection
Adult Dosing
- Inject 10‑30 mCi (370‑1110 MBq) IV; typical adult dose 15‑20 mCi (555‑740 MBq) for infection imaging
- Imaging performed 1–4 h post‑injection; additional delayed images at 24 h if needed
- Maximum cumulative activity per patient ≤ 30 mCi (1110 MBq) per study
Pediatric Dosing
- Weight‑based dosing 0.3‑0.5 mCi/kg (11‑18 MBq/kg) IV, not to exceed 10 mCi (370 MBq) total
- Minimum age for use generally ≥ 2 years; adjust dose for neonates/infants with caution
- Imaging timing same as adults (1–4 h post‑dose)
Indications
- Localization of acute bacterial infection and osteomyelitis
- Evaluation of prosthetic joint infection and soft‑tissue abscesses
- Differentiation of infection from sterile inflammation in fever of unknown origin
Mechanism of Action
- Murine IgG Fab′ fragment binds neutrophil‑specific NCA‑95 antigen
- 99mTc label emits γ‑rays (140 keV) enabling SPECT visualization of sites with active granulocyte accumulation
- Rapid clearance from blood pool reduces background activity, enhancing target‑to‑background ratio
Contraindications
- Known hypersensitivity to murine antibodies or any component of the kit
- Pregnancy and lactation unless benefit outweighs fetal radiation risk
- Severe renal impairment (eGFR < 15 mL/min) due to delayed clearance and increased radiation dose
Adverse Reactions
- Mild infusion reactions: flushing, pruritus, rash (≤ 5 % of patients)
- Rare anaphylaxis or severe hypersensitivity (≤ 0.1 %)
- Transient leukopenia or neutropenia (usually clinically insignificant)
- Radiation exposure–related risk (theoretical stochastic cancer risk)
Drug Interactions
- Concurrent administration of other radiopharmaceuticals may cause competitive binding or imaging interference
- High‑dose steroids or immunosuppressants can reduce granulocyte recruitment, lowering image sensitivity
- No clinically significant pharmacokinetic interactions with non‑radiopharmaceutical drugs
Curated Content: Needs Vetting Before Put to Clinical Use